The U.S. Department of Justice has moved state-licensed medicinal marijuana products from Schedule I to Schedule III under an order signed by acting Attorney General Todd Blanche, substantially reducing federal restrictions on products legal at the state level. The shift allows for expanded research, tax deductions for businesses, and represents a significant change in the federal government’s approach to cannabis as medicine.
Immediate Effects and Research Access
Under the new classification, state-licensed medical marijuana products will face looser federal regulation while remaining subject to rigorous oversight as Schedule III substances—similar to prescription drugs like acetaminophen with codeine. The reclassification opens doors for researchers to study state-legal cannabis products, a major change from the previous Schedule I status that limited studies to cannabis grown in federal facilities. Businesses selling medicinal marijuana legal under state law can now deduct business expenses from federal taxes.
The order follows President Donald Trump’s executive order directing the DOJ to move toward rescheduling. “This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information,” Blanche stated.
Broader Reclassification Process Ahead
The DEA has scheduled a hearing beginning June 29 and ending no later than July 15 to explore broader reclassification possibilities, including products that could include recreational use. Forty states and the District of Columbia currently allow medicinal marijuana.
Complexities for Hybrid Businesses
The order creates complications for the 24 states where recreational use is legal. Businesses selling both medicinal and recreational products may face a “transitional period in which federally covered medical activity and federally non-covered adult-use activity may be treated differently for registration, tax, and compliance purposes,” according to Chuck Smith, CEO of Colorado Leads. Recreational marijuana remains Schedule I and receives no tax benefits from the reclassification.
Industry leaders offer mixed reactions. Paul Armentano, deputy director of the National Organization for the Reform of Marijuana Laws, called the shift “historic” because the federal government has historically denied medical cannabis’s legitimacy. However, some industry representatives criticized the creation of multiple regulatory categories for a single plant species as creating artificial distinctions that complicate operations.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://royalexaminer.com/us-justice-department-downgrades-risk-of-state-licensed-medicinal-marijuana/